Current Affairs practice question for Railways, SSC, UPSC. Review the correct answer and explanation, then continue with related practice below.
Consider the following statements regarding ITVISMA: 1. It is a gene therapy for spinal muscular atrophy. 2. It was developed by Novartis. 3. It targets the defective SMN1 gene. 4. It is approved for patients aged two years and above, including adults. 5. The UAE became the second country after the United States to approve it for clinical use. Which of the statements given above are correct?
Correct Answerसही उत्तर
D. 1, 2, 3, 4 and 5D. 1, 2, 3, 4 और 5
Explanationव्याख्या
All five statements are correct according to the PDF.
ITVISMA is a one-time gene therapy developed by Novartis for spinal muscular atrophy.
It works by replacing the defective SMN1 gene and enabling production of SMN protein.
The therapy is approved for patients aged two years and above, including adults.
The UAE became the second country after the United States to approve it for clinical use.
PDF के अनुसार सभी five statements सही हैं। ITVISMA Novartis द्वारा developed one-time gene therapy है जो spinal muscular atrophy के लिए है। यह defective SMN1 gene को replace करके SMN protein का production enable करती है। Therapy two years और उससे अधिक age के patients, including adults, के लिए approved है। UAE, United States के बाद इसे clinical use के लिए approve करने वाला second country बना।
Practice More Like This
Vitorr selects questions using the same topic, subject, exam and overlapping concepts—not just database order.
Related Quizzes
Continue with quizzes connected to Current Affairs and Current Affairs. Sign up is required only when you start a quiz.